Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Genomic Profiling of Pancreatic Cystic Tumors
Not yet recruiting
- Conditions
- Pancreatic Cyst
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 250
- Registration Number
- NCT06195904
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
π°π·Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Tele-education in Ultrasound Training
Not Applicable
Completed
- Conditions
- Education, Medical, ContinuingTelemedicineUltrasonography
- Interventions
- Device: Head-Mounted Display (HMD) to communicate with a supervisor remotely
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06171828
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Remimazolam vs. Propofol: Impact on Postoperative Delirium in Neurosurgical Patients
Not Applicable
Recruiting
- Conditions
- Postoperative Delirium
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 696
- Registration Number
- NCT06115031
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Phase 2
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT06106802
- Locations
- π°π·
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
Modulating Surgery-Induced Blood-Brain Barrier Disruption in Elderly
Not Applicable
Recruiting
- Conditions
- Delirium, Postoperative
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 108
- Registration Number
- NCT06090955
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Recruiting
- Conditions
- Haploidentical Hematopoietic Stem Cell Transplantation
- Interventions
- Drug: ATG-LDPTCy
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06041893
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 51
- Registration Number
- NCT06015321
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Korea, Republic of
Mobile Chat Service for Parents of Children in Pediatric Emergency Room
Not Applicable
Recruiting
- Conditions
- Medical InformaticsEmergency MedicinePediatric Emergency Medicine
- Interventions
- Behavioral: ControlBehavioral: Information provided
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT06002542
- Locations
- π°π·
Samsung Medical Center, Seoul, Gangnam, Korea, Republic of
Comparison Physiological Effects According to Preoxygenation Method Using EIT
Not Applicable
Withdrawn
- Conditions
- Acute Hypoxemic Respiratory Failure
- Interventions
- Device: HFNC
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT05962073
- Locations
- π°π·
Samsung Medical Center, Seoul, Gangnam, Korea, Republic of
Exosome as the Prognostic and Predictive Biomarker in EBC Patients
Not Applicable
Active, not recruiting
- Conditions
- HER2-positive Breast CancerTriple Negative Breast Cancer
- Interventions
- Procedure: exosome and ctDNA evaluation
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT05955521
- Locations
- π°π·
Ji-Yeon Kim, Seoul, Korea, Republic of